Obstetrics & Gynecology Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Obstetrics & Gynecology 2005;105:953-961
© 2005 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Potts, R. O.
Right arrow Articles by Lobo, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Potts, R. O.
Right arrow Articles by Lobo, R. A.
Related Collections
Right arrow Basic Science
Right arrow Breast Disease
Right arrow Contraception
Right arrow General gynecology
Right arrow Internal Medicine
Right arrow Medical education
Right arrow Reproductive endocrinology

REVIEWS

Transdermal Drug Delivery: Clinical Considerations for the Obstetrician–Gynecologist

Russell O. Potts, PhD* and Rogerio A. Lobo, MD{dagger}

From *Russ Potts Consulting, LLC, San Francisco, California; and the {dagger}Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, New York, New York.

INTRODUCTION: The first transdermal drug delivery system was introduced in the United States over 20 years ago. Created as an alternative route of administration to improve patient compliance as well as to reduce side effects, the transdermal delivery of drugs now represents a $1.5 to $2 billion market and is growing rapidly.

DATA SOURCES: The medical literature from 1980 to 2005 was searched using the PubMed search engine. The search term was "transdermal," limited to human clinical trials. Abstracts were used to identify clinical trials that compared transdermal preparations and their oral counterparts in the same study.

TABULATION, INTEGRATION, AND RESULTS: In this article, we review the rationale for the transdermal administration of drugs; discuss aspects of the anatomy and physiology of the skin relevant to drug transport; examine the qualities required for a drug to be a good candidate for transdermal delivery; and consider key principles for the evaluation of the relative benefits of transdermal delivery, using studies of hormone replacement therapy and oral contraceptive as examples.

CONCLUSION: The data reviewed here suggest that certain clinical situations support the use of the transdermal administration of drugs over their oral counterparts.




This article has been cited by other articles:


Home page
 Obstet GynecolHome page
D. S. Guzick
Can Postmenopausal Women Patch Up Their Sex Lives With Testosterone?
Obstet. Gynecol., May 1, 2005; 105(5): 938 - 940.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American College of Obstetricians and Gynecologists.